Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Bruce Cozadd will deliver a corporate presentation and business update on January 14, 2025, at 9:45 a.m. PST.
The presentation will be accessible via webcast through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days post-conference. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, particularly in sleep disorders, epilepsy, and cancer treatments. The company maintains its headquarters in Dublin, Ireland, with research, development, and manufacturing facilities across multiple countries.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that CEO Bruce Cozadd plans to retire by the end of 2025, while continuing as Board Chair. The company's Board will conduct a comprehensive internal and external search for his successor, expected to conclude within 12 months.
Cozadd co-founded Jazz in 2003 and has served as CEO since 2009, transforming it into a global biopharmaceutical company with a focus on neuroscience and oncology. Under his leadership, the company grew to expect $4.0-4.1 billion in total revenue for 2024. Jazz currently employs approximately 2,800 people globally and maintains a commercialized portfolio with a differentiated pipeline of assets.
Jazz Pharmaceuticals (JAZZ) presented nine company-sponsored Epidiolex® (cannabidiol) posters at the American Epilepsy Society 2024 Annual Meeting. The presentations include real-world evidence from multiple studies showcasing the drug's effectiveness in treating rare epilepsies.
Key findings include: improvements in behavioral symptoms from the EpiCom trial; positive outcomes from the BECOME-TSC survey where 89% of caregivers plan to continue treatment; and results from the BECOME-LTC survey showing 85% of nurses reported reduced seizure frequency, with 49% noting over 50% reduction. The data also demonstrated Epidiolex's effectiveness in treating tuberous sclerosis complex (TSC), with median seizure reductions of 51%-87% in focal seizures and 44%-87% in total seizures.
Jazz Pharmaceuticals celebrates International Volunteers Day on December 5th, recognizing the global achievements of volunteers and the profound impact of volunteerism on society. This annual observance allows for reflection on community engagement efforts. Jazz Pharmaceuticals highlights its commitment to volunteerism and community engagement in its latest Corporate Sustainability and Social Impact Report. For more details, visit Jazz's profile on 3blmedia.com.
Jazz Pharmaceuticals announced that zanidatamab-hrii (Ziihera®) has been included in the NCCN Clinical Practice Guidelines as a category 2A treatment option for Biliary Tract Cancers (BTC). The drug, which received FDA accelerated approval on November 20, 2024, is now commercially available in the United States.
Ziihera is the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC. The approval was based on the HERIZON-BTC-01 clinical trial results, which showed a 52% objective response rate and median duration of response of 14.9 months. The drug is indicated for adults with previously treated, unresectable or metastatic HER2-positive BTC.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced a webcast scheduled for December 11, 2024, at 4:30 p.m. ET to discuss Ziihera® (zanidatamab-hrii), their recently approved chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC). The presentation will cover clinical data, patient needs, and commercialization strategy.
The FDA granted accelerated approval to Ziihera on November 20, 2024, for treating adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC. Dr. Shubham Pant from MD Anderson Cancer Center will discuss data from the HERIZON-BTC-01 trial during the webcast.
Jazz Pharmaceuticals (JAZZ) announced presentations at two major medical conferences: the 2024 San Antonio Breast Cancer Symposium (SABCS) and the 66th American Society of Hematology (ASH) Annual Meeting. At SABCS, the company will present two abstracts focusing on Ziihera® (zanidatamab-hrii), including a Phase 3 trial design and new data from a Phase 1b/2 study in HER2-positive breast cancer patients.
At ASH, Jazz will showcase 13 abstracts, primarily featuring research on Vyxeos® and Defitelio®. The presentations include multiple Phase 3 trials and studies examining various combination therapies for acute myeloid leukemia (AML) and other blood cancers. This extensive research portfolio demonstrates Jazz's commitment to advancing cancer treatment options.
Jazz Pharmaceuticals announced FDA accelerated approval of Ziihera (zanidatamab-hrii) for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). The approval is based on the HERIZON-BTC-01 trial results showing a 52% objective response rate and 14.9 months median duration of response. Ziihera is the first dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing, and continued approval may be contingent upon verification of clinical benefit.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management will engage in a fireside chat on December 3, 2024, at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. GMT. An audio webcast will be available through the company's investor website and archived for 30 days.
Jazz Pharmaceuticals is a global biopharma company focusing on developing life-changing medicines for serious diseases. The company maintains a diverse portfolio of marketed medicines for sleep disorders and epilepsy, along with cancer treatments. Based in Dublin, Ireland, Jazz operates research, development, and manufacturing facilities across multiple countries.
Jazz Pharmaceuticals announced its Q3 2024 financial results, reporting a 14% year-over-year revenue increase driven by key products Xywav, Epidiolex, and Rylaze. The company affirmed its 2024 total revenue guidance of $4.0 to $4.1 billion.
Key highlights include:
- Record revenues of over $1.05 billion.
- Strong demand for Xywav with 400 net patient additions.
- Anticipated launch of Zanidatamab for BTC in Q4 2024.
- Plan to submit sNDA for Zepzelca in 1H 2025.
Financial highlights show a GAAP net income of $215.1 million and a non-GAAP adjusted net income of $416.9 million. The company completed a $1 billion senior notes offering and repurchased $150 million of its shares.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
